Biogen Cuts Full-Year EPS Guidance Despite Strong Q1 Results and Strategic Acquisitions

summarizeSummary

Biogen reported strong Q1 results but lowered its full-year EPS guidance by $1.00 due to IPR&D charges from strategic acquisitions, while also announcing progress in its pipeline and the proposed acquisition of Apellis.

check_boxKey Events

• Strong Q1 Financial Performance

  Biogen reported first quarter 2026 total revenue of $2.5 billion, an increase of 2% year-over-year. GAAP diluted EPS rose 31% to $2.15, and Non-GAAP diluted EPS increased 18% to $3.57. Growth products like LEQEMBI, SKYCLARYS, and ZURZUVAE demonstrated continued strong commercial execution.

• Full-Year EPS Guidance Lowered

  The company updated its full-year 2026 Non-GAAP diluted EPS guidance, reducing the expected range from $15.25-$16.25 to $14.25-$15.25. This $1.00 reduction is primarily due to approximately $1.00 in acquired IPR&D charges from ongoing business development activities, including the felzartamab deal and an expected milestone.

• Strategic Acquisitions and Pipeline Progress

  Biogen announced the proposed acquisition of Apellis Pharmaceuticals, expected to be accretive in 2027 and materially increase Non-GAAP diluted EPS compounded annual growth rate. The company also secured exclusive rights to felzartamab in Greater China and reported positive new data across key late-stage pipeline programs, including Litifilimab, Salanersen, and LEQEMBI persistence.

auto_awesomeAnalysis

Biogen reported a mixed quarter, with strong first-quarter financial results overshadowed by a significant reduction in its full-year 2026 Non-GAAP diluted EPS guidance. While Q1 revenue and EPS showed healthy year-over-year growth, the company lowered its EPS forecast by $1.00 per share, citing acquired IPR&D charges related to ongoing business development activities, including the acquisition of felzartamab rights in Greater China. This guidance cut, despite being attributed to investments in future growth, typically leads to negative market sentiment. However, the company also highlighted progress in its growth products, positive late-stage pipeline data, and the proposed acquisition of Apellis Pharmaceuticals, which is expected to bolster long-term revenue and earnings growth. Investors will likely focus on the revised guidance and the implications of these strategic investments on near-term profitability versus long-term growth potential.